Form 4: Ptc Therapeutics Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Neil Gregory Almstead, CHIEF TECHNICAL OPS OFFICER of Ptc Therapeutics, Inc., sold 2,464 shares of common stock on July 9, 2026 for $90.25 per share.

Summary

  • Option exercise/conversion: acquired 2,464 Common Stock at $46.54 ($114,675) on July 9, 2026; holds 62,763 after (Direct).
  • Open-market sale: disposed of 2,464 Common Stock at $90.25 ($222,376) on July 9, 2026; holds 60,299 after (Direct).
  • Option exercise/conversion: disposed of 2,464 Stock Option (Right to Buy) on July 9, 2026; holds 45,036 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $222,376 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Neil Gregory Almstead — Officer (CHIEF TECHNICAL OPS OFFICER)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-07-09Option exercise/conversionCommon Stock2,464$47$114.7K62,763
2026-07-09Open-market saleCommon Stock2,464$90$222.4K60,299
2026-07-09Option exercise/conversionStock Option (Right to Buy)2,464——45,036

Key Dates

DateDescription
2026-07-09Option exercise/conversion (2,464 shares)
2026-07-09Open-market sale (2,464 shares)
2026-07-09Option exercise/conversion (2,464 shares)

Keywords

insider transaction, Form 4, PTCT, PTC THERAPEUTICS, INC., bearish, Neil Gregory Almstead

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.